2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call Exhibit 99.1 Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup Purchase ...

Core Insights - Cognition Therapeutics, Inc. reported positive results from Phase 2 studies of zervimesine (CT1812) for dementia with Lewy bodies (DLB) and Alzheimer's disease, indicating significant potential for these neurodegenerative disorders [1][4][5] - The company plans to advance zervimesine into late-stage trials for both DLB and Alzheimer's disease, with meetings scheduled with the FDA to discuss Phase 3 clinical protocols [3][4] Clinical Developments - Phase 2 SHIMMER study results showed up to 91% slowing of cognitive decline compared to placebo after 6 months of zervimesine treatment in DLB patients [5] - Phase 2 SHINE study results indicated near-total preservation of cognition in Alzheimer's patients with lower p-tau217 levels treated with zervimesine [5] - The company has concluded enrollment in the Phase 2 dry AMD study to focus resources on Alzheimer's and DLB programs [2][7] Financial Overview - As of December 31, 2024, cash and cash equivalents were approximately $25.0 million, with total obligated grant funds remaining from the NIA at $50.0 million [8][16] - Research and development expenses increased to $41.7 million in 2024 from $37.2 million in 2023, primarily due to costs associated with ongoing Phase 2 trials [8][9] - The company reported a net loss of $34.0 million for 2024, compared to a net loss of $25.8 million in 2023, with a consistent loss per share of $(0.86) [9][15] Strategic Initiatives - The company is actively evaluating funding options for clinical trials, including potential partnerships with pharmaceutical companies [4] - A novel chemical process for zervimesine manufacturing has been developed, with provisional patent applications filed as part of the Phase 3 readiness plan [5]

Conference Call and Live Audio Webcast Scheduled for March 20, 2025PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 20, 2025, before the market open. Following the release, management will host a conference call at 8:00 a. ...

PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by the Nasdaq Stock Market LLC (“Nasdaq”) on September 12, 2024 that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days. As a result, Cognition was given 180 calendar days to regain compliance with the minim ...

PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her presentation, Ms. Ricciardi will review plans for 2025 to support the advancement of zervimesine (CT ...

Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMDPURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscript reviewing recent work supporting the potential of zervimesine (CT1812), a small molecule drug candidate to treat dry age-related macular degener ...

Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 Months Experienced Slower Lesion Growth than Participants Receiving Placebo Following the Futility Analysis, Management Concluded the Phase 2 Study, Preserving Capital Full Analysis will be Provided in the Second Quarter of 2025 PURCHASE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported a positive outcome o ...

Core Insights - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, particularly Alzheimer's disease and dementia with Lewy bodies [4] Group 1: Workshop and Presentation - Dr. Mary Hamby will co-host a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit, focusing on participant screening methods for clinical trials [1] - The workshop will include an overview of findings from Cognition's Phase 2 'SHINE' study of zervimesine (CT1812), highlighting that participants with lower p-tau217 levels showed a 95% improvement on the ADAS-Cog 11 scale and a 108% improvement on the MMSE scale compared to placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays are suggested to be valuable not only as a diagnostic tool but also for identifying Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid [3] - The measurement of plasma p-tau217 can be conducted through a simple blood test, aiding in the personalization of treatment regimens for patients [3] Group 3: Company Overview - Cognition Therapeutics is currently investigating zervimesine in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study in early Alzheimer's disease [4] - Zervimesine is believed to interact with the sigma-2 receptor, offering a distinct mechanism for treating degenerative diseases [4]

Core Insights - Cognition Therapeutics, Inc. is advancing its clinical-stage drug development focused on neurodegenerative disorders, particularly Alzheimer's disease, with a significant emphasis on precision medicine [1][4] Group 1: Clinical Developments - Dr. Mary Hamby will co-host a workshop at the Hanson Wade Neuroimmunology Drug Development Summit to discuss participant screening methods for clinical trials [1] - The Phase 2 'SHINE' study of zervimesine (CT1812) showed that participants with lower p-tau217 levels had a 95% better score on the ADAS-Cog 11 scale and 108% better on the MMSE scale compared to those on placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays can serve as a diagnostic tool to identify Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid, enhancing personalized treatment approaches [3] Group 3: Company Overview - Cognition Therapeutics is focused on developing small molecule therapeutics for age-related degenerative disorders, with zervimesine being investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease [4]

Core Insights - Cognition Therapeutics, Inc. has developed a novel chemical process for manufacturing zervimesine (CT1812), enhancing its stability at room temperature and supporting future clinical studies and potential commercial manufacturing [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders, particularly targeting Alzheimer's disease and dementia with Lewy bodies [4] - The company is currently investigating zervimesine (CT1812) in clinical programs, including the ongoing START study for early Alzheimer's disease [4] Product Information - Zervimesine (CT1812) is an investigational oral medication designed to treat central nervous system diseases, specifically targeting the toxic effects of amyloid beta (Aβ) and ɑ-synuclein proteins that damage neurons [3] - The new manufacturing process utilizes innovative technologies such as high throughput screening and light-induced continuous flow processing, which improves the efficiency and safety of zervimesine synthesis [2]